Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of three Telisotuzumab Vedotin dosing regimens in previously treated c-Met overexpressing EGFR wild-type advanced nonsquamous NSCLC
CTR20250985Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of telisotuzumab vedotin in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Mar 2025; status: active.
02
Drugs
telisotuzumab vedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250985.